ClinicalTrials.gg
Sign In
CompletedNCT05723016Updated Feb 10, 2023

Anti-Müllerian Hormone and Embryo Aneuploidy

An observational study in Infertility and Aneuploidy, sponsored by Clinica de la Mujer Medicina Reproductiva, Chile. Completed at 1 site in Chile. Open to female participants. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Clinica de la Mujer Medicina Reproductiva, Chile · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Sex
Female
01

Study summary

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels.

Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

02

Conditions studied

  • Infertility
  • Aneuploidy

Keywords

  • AMH
  • IVF
  • Aneuploidy
  • PGT-a
  • anti-mullerian hormone
  • oocyte quality
03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's enrollment of 300 is above the median of 200 across 592 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Clinica de la Mujer Medicina Reproductiva, Chile is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who underwent a first IVF cycle with PGT-A at the blastocyst stage

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.

Exclusion criteria

Exclusion Criteria:

  • Data from oocyte donation cycles
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • AMH < 0.5 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

  • AMH 0.5-0.99 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

  • AMH 1.0-1.49 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

  • AMH 1.5-1.99 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

  • AMH 2.0-4.99 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

  • AMH > 5.0 ng/ml

    Other: preimplantation genetic test for aneuploidies (PGT-a)

Interventions

  • Otherpreimplantation genetic test for aneuploidies (PGT-a)

    preimplantation genetic test for embryo aneuploidies after IVF

06

What researchers measure

Primary outcomes

  1. Aneuplody rate

    Time frame: 4 years

Secondary outcomes

  1. Clinical pregnancy rate

    Time frame: 4 years

  2. Miscarriage rate

    Time frame: 4 years

07

Study locations

1 site
  • Clinica de la Mujer Medicina Reproductiva
    Viña Del Mar, Valparaíso 2520187, Chile
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Dec 2022, 59 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 10, 2023
StartActual
Jan 1, 2018
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05723016
Lead sponsor
Clinica de la Mujer Medicina Reproductiva, Chile
Responsible party
Jose Antonio Moreno (MD, PhD, Clinica de la Mujer Medicina Reproductiva, Chile) — Principal investigator
First posted
Feb 10, 2023
Start date
Jan 1, 2018
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Feb 10, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infertility →

Other studies from this sponsor

Clinica de la Mujer Medicina Reproductiva, Chile

Start the discussion